Cyclerion Therapeutics (CYCN) Common Equity (2018 - 2025)

Cyclerion Therapeutics' Common Equity history runs 8 years deep, the most recent figure standing at $9.1 million for Q4 2025.

• In Q4 2025, Common Equity rose 2.66% year-over-year to $9.1 million; the TTM figure through Dec 2025 stood at $9.1 million (up 2.66% YoY), while the FY2025 annual figure was $9.1 million, up 2.66% from the prior year.
• Common Equity was $9.1 million for Q4 2025 at Cyclerion Therapeutics, down from $9.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $65.2 million in Q2 2021 to a low of $3.9 million in Q1 2023.
• Historically, Common Equity has averaged $20.6 million across 5 years, with a median of $10.2 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Common Equity sank 89.4% in 2023, then soared 152.82% in 2024.
• A 5-year view of Common Equity shows it stood at $48.2 million in 2021, then plunged by 78.34% to $10.5 million in 2022, then climbed by 8.0% to $11.3 million in 2023, then retreated by 21.6% to $8.8 million in 2024, then increased by 2.66% to $9.1 million in 2025.
• The last three Common Equity figures came in at $9.1 million (Q4 2025), $9.5 million (Q3 2025), and $8.6 million (Q2 2025), per Business Quant data.